AiCure Secures $68.8M to Advance AI-Powered Medication Adherence Monitoring Platform

Jan 30, 2024 09:00 CST Updated 09:00

AiCure

AI Medical Service Provider

Due to recent changes in the official account push mechanism, we welcome you to set Boom Health as a "starred" account on the homepage of the official account to get the latest trends and expert insights in the digital healthcare industry第一时间!

On January 23, AiCure, a developer of AI systems for medication adherence, secured $16 million in new funding. AiCure offers a SaaS platform that applies machine learning, computer vision, and big data to healthcare, enhancing the predictability of research timelines, reducing costs, and accelerating progress through remote patient engagement and assessment, including the measurement of digital biomarkers and real-time monitoring of patient medication dosage.

This article is approximately 1400 words and requires 3 minutes to read.

AiCure, LLC was founded in 2010, with its headquarters located in New York, USA. The company develops a patient engagement and monitoring platform based on artificial intelligence, helping researchers and clinicians understand and predict patients' responses to treatment. Its proprietary intelligent software platform captures and analyzes video, audio, and behavioral data to establish direct connections between patients, diseases, and treatments. The platform uses the camera of a tablet or smartphone to capture physiological data points related to patients' expressiveness, psychomotor functions, and cognition while taking medication. It then analyzes the data from the camera through an AI system to ensure patients take their medications correctly and issues warnings if patients fail to take their medications or do so incorrectly.

Since 2013, AiCure has completed five rounds of financing totaling $68.8 million:

Patient medication adherence has a significant impact on the effectiveness of treatment. Currently, nearly one-third of clinical trials fail due to improper patient medication use, and annually, over 100,000 deaths are caused by not adhering to prescribed medications. AiCure's solution is expected to change this situation. AiCure focuses on medication adherence management. Through the company’s developed Patient Connect mobile application, healthcare institutions or researchers can provide users with real-time dosing instructions, remotely assess patient medication intake using smartphones, computer vision, and AI, while activating dosing support for all administration routes and methods to ensure medication adherence.

This solution can be used on any mobile device with a camera. AiCure uses mobile technology and facial recognition to collect patient data through an app, employing algorithms to identify whether patients have prepared the correct medication and whether they have taken it, then sends the data back to healthcare providers or researchers. All patient data observed via the AiCure platform is encrypted and anonymized, with voice and text information integrated into a cloud-based dashboard, ensuring compliance with HIPAA regulations.

Overall, this solution can address three major pain points:

Track the entire course of drug treatment, reduce the risk of data loss, and help researchers determine whether patients need support to maintain their treatment plans.
Detect whether the patient has taken the medication, allowing researchers to intervene before the patient's non-adherence affects the trial.
Training patients on safe medication use can be applied when patients self-administer drugs in unconventional ways.

In this process, the AiCure platform aggregates and integrates patient medication-related information while anonymizing sensitive data to ensure the privacy and security of patient information. Meanwhile, based on this data, researchers can determine throughout the study the likelihood of patients adhering to or discontinuing treatment/clinical trials. Additionally, patient-centered interventions can be implemented to provide personalized support, focusing efforts on those most in need.

The AiCure platform allows pharmaceutical and biotechnology companies to remotely collect and analyze objective, quantifiable physiological and behavioral data using digital biomarkers and predictive analytics to optimize drug development and patient care. Currently, the digital biomarkers and indications available through AiCure include:

Major Depressive Disorder: Facial expressions, speech expression, head movement speed
PTSD: Facial expressions, movements, speech expression
Essential Tremor: Hand Movement
Parkinson's Disease: Facial tremor, Emotion, Harmonic noise ratio, Speech rate
Tardive Dyskinesia:Movements of the face, lips, jaw, and tongue
Schizophrenia:Head Movement

AiCure provides end-to-end customized support for research centers and monitors metrics related to participants' adherence, compliance, data management, and technology usage in studies. The company’s clinical service staff, equipped with deep professional expertise, collaborate with study coordinators to understand current pain points in trials, offer data-driven recommendations, and actively support patient engagement to ensure high-quality research execution and participant satisfaction. As AI continues to advance, AiCure's technology will be more widely applied, enabling better healthcare services for patients.

Author: Zhang Qiankun

Share

Like